Sanofi India Limited has informed the Exchange regarding Appointment of Mr. Rahul Bhatnagar as Chairman of the company w.e.f. April 30, 2026.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanofi India Limited reported Q4 FY2026 unaudited financial results with revenue from operations of ₹4,723 million, down from ₹5,359 million in Q4 FY2025, while profit for the quarter increased to ₹1,026 million from ₹1,195 million in the same period last year. The Board approved appointment of Mr. Rahul Bhatnagar (Independent Director) as Chairman effective April 30, 2026. Two Independent Directors, Mr. Aditya Narayan and Mrs. Usha Thorat, completed their tenure on April 29, 2026. All board committees were reconstituted effective April 30, 2026. The insulin portfolio delivered double-digit growth for the second consecutive quarter, though overall results were impacted by partnership transitions.
The appointment of Mr. Bhatnagar as Chairman provides board continuity as two long-serving independent directors depart. The revenue decline but profit improvement suggests cost efficiency focus despite challenging market conditions from partnership transitions.